Owen Wallace is leaving Novartis (NYSE: [[ticker:NVS]]) to become chief scientific officer of Cambridge, MA-based Fulcrum Therapeutics. At Novartis, Wallace was head of the company’s global discovery chemistry division. His experience also includes positions at Eli Lilly (NYSE: [[ticker:LLY]]) and Bristol-Myers Squibb (NYSE: [[ticker:BMY]]). Fulcrum aims to treat treat genetic conditions by developing drugs that control the “on and off switches” of disease genes.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
